Guggenheim analyst Vamil Divan initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $9 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ELDN: Eledon Pharmaceuticals highlights recent business milestones, 2025 outlook Eledon Pharma Adjusts CEO Bonus Structure